[InnoCare Pharma: BCL2 inhibitor ICP-248 approved for clinical treatment of acute myeloid leukemia] Jinshi Data reported on September 19 that InnoCare Pharma announced today that the company's independently developed BCL2 inhibitor ICP-248 combined with azacitidine for the treatment of acute myeloid leukemia (AML) has been approved for clinical use in China. BCL2 is an important regulatory protein in the cell apoptosis pathway, and its abnormal expression is associated with the occurrence and development of a variety of malignant blood tumors. ICP-248 is a new oral, highly selective BCL2 inhibitor that selectively inhibits BCL2 and restores the programmed cell death mechanism of tumor cells, thereby exerting anti-tumor efficacy. (Reprinted from: Jinshi Data)